title: Population pharmacokinetics of aripiprazole in healthy Korean subjects.
abstract: OBJECTIVE
  Aripiprazole is widely used to treat schizophrenia and bipolar disorder. This study aimed to develop a combined population pharmacokinetic model for aripiprazole in healthy Korean subjects and to identify the significant covariates in the pharmacokinetic variability of aripiprazole.
  
  
  METHODS
  Aripiprazole plasma concentrations and demographic data were collected retrospectively from previous bioequivalence studies that were conducted in Chonbuk National University Hospital. Informed consent was obtained from subjects for cytochrome P450 (CYP) genotyping. The population pharmacokinetic parameters of aripiprazole were estimated using nonlinear mixed-effect modeling with first-order conditional estimation with interaction method. The effects of age, sex, weight, height, and CYP genotype were assessed as covariates.
  
  
  RESULTS
  A total of 1,508 samples from 88 subjects in three bioequivalence studies were collected. The two-compartment model was adopted, and the final population model showed that the CYP2D6 genotype polymorphism, height and weight significantly affect aripiprazole disposition. The bootstrap and visual predictive check results were evaluated, showing that the accuracy of the pharmacokinetic model was acceptable.
  
  
  CONCLUSIONS
  A population pharmacokinetic model of aripiprazole was developed for Korean subjects. CYP2D6 genotype polymorphism, weight, and height were included as significant factors affecting aripiprazole disposition. The population pharmacokinetic parameters of aripiprazole estimated in the present study may be useful for individualizing clinical dosages and for studying the concentration-effect relationship of the drug.
authors.forename: Ji-Young
authors.initials: JY
authors.lastname: Jeon
authors.forename: Soo-Wan
authors.initials: SW
authors.lastname: Chae
authors.forename: Min-Gul
authors.initials: MG
authors.lastname: Kim
mesh_terms: D014150:Antipsychotic Agents / Q000493:pharmacokinetics*; D000068180:Aripiprazole / Q000493:pharmacokinetics*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D012189:Retrospective Studies
chemical_list: D014150:Antipsychotic Agents; D000068180:Aripiprazole; D019389:Cytochrome P-450 CYP2D6